Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:

NCT ID: NCT03012620 Completed - Sarcoma Clinical Trials

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

AcSé
Start date: July 5, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available, in order to identify subsets of patients that may benefit from treatment

NCT ID: NCT02973997 Completed - Clinical trials for Poorly Differentiated Thyroid Gland Carcinoma

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02966093 Completed - Clinical trials for Differentiated Thyroid Cancer (DTC)

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Start date: January 11, 2017
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo.

NCT ID: NCT02947035 Completed - Thyroid Cancer Clinical Trials

Molecular Testing to Direct Extent of Initial Thyroid Surgery

Start date: February 1, 2017
Phase: Phase 2
Study type: Interventional

The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.

NCT ID: NCT02911155 Completed - Breast Cancer Clinical Trials

Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists

Start date: September 21, 2016
Phase:
Study type: Observational

Background: The field of nuclear medicine has changed a lot in the past decades. Technology has gotten better, so patients are exposed to less radiation. But now workers are doing procedures more often and using lead aprons less. So they may be exposed to more radiation. This may put them at higher risk for cancers and other health problems that are related to radiation. Researchers want to collect data from technologists to learn more about the risks and appropriate doses of radiation. Objective: To learn more about the risks and appropriate doses of radiation for nuclear medicine technologists. Eligibility: Adults who were first certified in nuclear medicine technology in the United States after 1980. They must be living in the United States. They must not be participants in the USRT study. Design: Participants will be recruited online. Participants will complete an online survey. It will take about a half hour. This will have questions about their work with nuclear medicine procedures. There will be questions about the kinds of procedures and how often they do them. Participants will give a short work history. This will include the names of current and past employers. Participants will allow researchers to get records of their film badge dose readings. These will come from dosimetry providers. Dosimetry data will not be shared with participants. Researchers can t ensure the how accurate or complete the data are.

NCT ID: NCT02878044 Completed - Thyroid Cancer Clinical Trials

Shared Decision Making in Patients With Thyroid Nodules

Start date: August 18, 2016
Phase: N/A
Study type: Interventional

The objective of this project is to evaluate a treatment decision aid for patients with low risk thyroid cancer.

NCT ID: NCT02870569 Completed - Clinical trials for Differentiated Thyroid Cancer

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Start date: September 2016
Phase: Phase 2
Study type: Interventional

Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

NCT ID: NCT02862470 Completed - Thyroid Cancer Clinical Trials

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

Start date: August 5, 2016
Phase:
Study type: Observational [Patient Registry]

The investigators expected to enroll 30 patients with papillary, follicular or anaplastic thyroid cancer, and collect their urine samples before operation, immediately after operation, post-operative 3, 6 12 months. The investigators will analyze the urine exosomal proteins and probable biological markers. The investigators hope to find the prognostic biological markers via this prospective study. The investigators further hope to find newly therapeutic mechanism and medications for such patients with poorly-differentiated or anaplastic thyroid cancer.

NCT ID: NCT02856347 Completed - Clinical trials for Medullary Thyroid Cancer

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

CMTpostopFDOPA
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease. This is an inter-regional multicentric, prospective study evaluating the benefit of PET F-DOPA imaging in involved node detection compared to standard imaging assessment in patient with medullary thyroid cancer. The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging. Obtained data will be compared to the "gold standard" based on : - nodes cytology when they could be punctured - histology when a new surgery will be recommended - surveillance when the 2 first cases will be not applicable (imaging monitoring, evolution of thyrocalcitonin)

NCT ID: NCT02826746 Completed - Thyroid Neoplasms Clinical Trials

Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy

Start date: July 2016
Phase: N/A
Study type: Interventional

The primary purpose of this study is to investigate the effect of intravenous magnesium on postoperative throat pain after thyroidectomy. The secondary purpose of this study is to investigate the effect of intravenous magnesium on total dose of fentanyl in recovery room after thyroidectomy.